Insulet (PODD)
(Delayed Data from NSDQ)
$171.40 USD
+2.22 (1.31%)
Updated Mar 28, 2024 04:00 PM ET
After-Market: $171.41 +0.01 (0.01%) 7:58 PM ET
2-Buy of 5 2
C Value A Growth D Momentum B VGM
Brokerage Reports
Insulet Corporation [PODD]
Reports for Purchase
Showing records 161 - 180 ( 338 total )
Company: Insulet Corporation
Industry: Medical - Products
Monthly Neulasta Onpro Kit Prescription Tracker Points to Significant Sequential Share Gain (However July Data May Be an Anomaly); Maintain OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
HEALTHCARE - 2016 PacGrow Healthcare Conference Day 1
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Insulet Corporation
Industry: Medical - Products
Medical Devices - Day 1: Key Takeaways from the PacGrow Healthcare Conference
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Biotechnology/Biopharmaceuticals - 2016 PacGrow Healthcare Conference Day 1
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Insulet Corporation
Industry: Medical - Products
Q2 well ahead, guidance raised, reiterate BUY, raising target to $39.25
Provider: Feltl & Company
Analyst: HAYNOR B
Company: Insulet Corporation
Industry: Medical - Products
2Q Results Highlighted by a Multitude of Positive Surprises; Increasing PT to $48 - Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Company: Insulet Corporation
Industry: Medical - Products
Insulet Corp. with OUTPERFORM: Onpro Kit exits 2Q with 40% share of Neulasta franchise and Continues to Grow
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Insulet Corp.with OUTPERFORM: Monthly Neulasta Onpro Kit Prescription Tracker Points To Further Share Gains; Setback To Novartis Biosimilar Positive For OPK; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Medical Devices: 2Q16 MedTech Preview: Stable Trends and Healthy Underlying Fundamentals
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Diabetes: Artificial Pancreas Workshop Provides Insights On the Future of the Diabetes Market
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Monthly Neulasta Onpro Kit Prescription Tracker Points Toward Further Share Gains in May; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
American Diabetes Association Meeting Suggests a Diabetes Technology Renaissance Is Coming; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Neulasta Onpro Kit Prescriptions Continue to Gain Share in April; Maintain OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
International OmniPod Demand Expected to Remain Robust; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
MDT/UHC Insulin Pump Agreement Could Become A Significant POSITIVE for the Other
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Volatility in Diabetes Stocks Following UNH/MDT Agreement Creates Buying Opportunity; Reiterate OUTPERFORM on DXCM, PODD, TNDM
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Growth unleashed following Neighborhood Diabetes divestment, reiterate BUY
Provider: Feltl & Company
Analyst: HAYNOR B
Company: Insulet Corporation
Industry: Medical - Products
Steady Improvements with Healthy Underlying Momentum Across All Segments; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Feltl Insulin Pump Project: Historical survey of ~6,000 users
Provider: Feltl & Company
Analyst: HAYNOR B